Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Optifree RepleniSH + ReNu Multiplus
- Development stage
- Unknown
- Lead developer
- Alcon
- Modality
- Small Molecules
- Administration
- Ophthalmic
01
Overview
This entry refers to a clinical study comparison between two multipurpose contact lens disinfecting solutions (MPDS): **Optifree RepleniSH** and **ReNu Multiplus**. Optifree RepleniSH, developed by Alcon, utilizes the TearGlyde reconditioning system (including Tetronic 1304 and C9-ED3A) along with Polyquad (polyquaternium-1) and Aldox (myristamidopropyl dimethylamine) preservatives to maintain moisture and disinfect lenses. ReNu Multiplus, developed by Bausch + Lomb, contains Hydranate (hydroxyalkylphosphonate) for protein removal, poloxamine for wetting, and Dymed (polyaminopropyl biguanide) as a disinfectant. The study conducted by the University of Waterloo (NCT00415376) evaluated the effects of these care regimens on corneal and conjunctival sensitivity and staining in soft contact lens wearers with myopia or hyperopia.
- Brand names
- Optifree RepleniSHReNu MultiplusOpti-Free RepleniSH
- Other names
- NCT00415376 interventionNCT-00415376 interventionNCT 00415376 intervention
Beyond the preview
Go deeper on Optifree RepleniSH + ReNu Multiplus.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Optifree RepleniSH + ReNu Multiplus.